首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >THE CRAVE OF FIXED DOSE COMBINATION IN INDIAN MARKET
【24h】

THE CRAVE OF FIXED DOSE COMBINATION IN INDIAN MARKET

机译:印度市场固定剂量组合的渴望

获取原文
获取外文期刊封面目录资料

摘要

The aim of the present retrospective works reveals the need of fixed-dose combination (FDC) in Indian market as per the Indian regulations. A combination drug most commonly refers to an FDC, which is a formulation including two or more active pharmaceutical ingredients combined in a single dosage form, which is manufactured and distributed in certain respective fixed doses. This review outlines the FDCs rationale, guidelines on data required for approval for marketing FDCs, marketing potential throughout the world. The safety of the combination drugs has to be thoroughly evaluated, and there are considerations for the drugs that are already in the market as individual or single-drug entity. However, the safety profile of the established drugs will alter when they are combined together. However, many of the irrational combinations are popular and widely prescribed by physicians in our country. This study provides a comprehensive analysis of the current markets for FDC products throughout the world and the market potential of promising drugs under development.
机译:本回顾性研究的目的表明,根据印度法规,印度市场需要固定剂量组合(FDC)。组合药物最通常是指FDC,其是包括以单一剂型组合的两种或更多种活性药物成分的制剂,其以某些相应的固定剂量制造和分布。此次审查概述了FDC的基本原理,批准营销FDC所需数据的准则,遍布全球的营销潜力。组合药物的安全性必须进行彻底评估,对于作为个体或单一药物实体已经在市场上出售的药物,需要考虑一些因素。但是,现有药物组合在一起时,其安全性将发生变化。但是,许多不合理的组合在我国医师中很流行并且广泛使用。这项研究对全球FDC产品的当前市场以及正在开发的有前途的药物的市场潜力进行了全面分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号